Trial Profile

Phase 2 study of REN001 in LC-FAOD patients

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 19 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mavodelpar (Primary)
Indications Metabolic disorders
Focus Therapeutic Use

Most Recent Events

27 Mar 2023 According to a Reneo Pharmaceuticals media release, the company expect to finalize plans for the LC-FAOD Phase 2 program later this year.
15 Nov 2022 New trial record
08 Nov 2022 According to a Reneo Pharmaceuticals media release, meeting with regulatory agencies to discuss to discuss this study is expected in the fourth quarter of 2022 and update to be provided in the first quarter of 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com